Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial.

BACKGROUND Sublingual immunotherapy (SLIT) is a recognized and safe treatment for allergic rhinitis and conjunctivitis. The aim was to evaluate the efficacy and safety of tablets for grass and rye pollen- induced rhinitis and conjunctivitis. METHODS A double-blind, randomized, placebo-controlled trial was carried out over 9 months. 105 patients received a standardized grass/rye mix extract or a placebo using sublingual drops during the build-up phase. Drops were replaced by sublingual tablets during the maintenance phase (300 IR/daily). RESULTS In patients that received active treatment, a significantly lower total symptom score (rhinitis and conjunctivitis) compared to the placebo group was observed (p = 0.038). The investigators' assessment revealed a significant improvement in favor of the active treatment group (p = 0.018). Skin reactivity to grass and rye pollen was significantly reduced in the active treatment group (p < 0.05). No statistical difference was observed between the two groups for serum-specific IgG4 levels. Side effects were local and mild, and no severe systemic reactions were reported. CONCLUSION This study indicates that tablet-based sublingual immunotherapy was safe and significantly improved grass/rye pollen-induced rhinoconjunctivitis symptoms. It was also associated with a significant inhibition of the immediate skin response.

[1]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis , 2010 .

[2]  Stacie M Jones,et al.  Sublingual Immunotherapy With Once-Daily Grass Allergen Tablets: A Randomized Controlled Trial in Seasonal Allergic Rhinoconjunctivitis , 2007, Pediatrics.

[3]  B. Riis,et al.  Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage , 2007, Allergy.

[4]  M. Calderon,et al.  Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy , 2007, Allergy.

[5]  S. Durham,et al.  Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. , 2006, Journal of Allergy and Clinical Immunology.

[6]  B. Niggemann,et al.  The Upper Airway a Prospective, Randomized, Double-blind, Placebo-controlled Multi-centre Study on the Efficacy and Safety of Sublingual Immunotherapy (slit) in Children with Seasonal Allergic Rhinoconjunctivitis to Grass Pollen the Safety of Sublingual-swallow Immunotherapy: an Analysis of Publishe , 2022 .

[7]  Helen E. Smith,et al.  Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. , 2004, The Journal of allergy and clinical immunology.

[8]  C. André,et al.  A Double-Blind Placebo-Controlled Evaluation of Sublingual Immunotherapy with a Standardized Ragweed Extract in Patients with Seasonal Rhinitis , 2003, International Archives of Allergy and Immunology.

[9]  P. Rufin,et al.  Safety of Various Dosage Regimens during Induction of Sublingual Immunotherapy , 2002, International Archives of Allergy and Immunology.

[10]  S. Durham,et al.  Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  J. Bousquet,et al.  Allergic rhinitis and its impact on asthma. , 2001, The Journal of allergy and clinical immunology.

[12]  C. André,et al.  Safety of Sublingual-Swallow Immunotherapy in Children and Adults , 2000, International Archives of Allergy and Immunology.

[13]  G. Canonica,et al.  Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. , 1999, The Journal of allergy and clinical immunology.

[14]  A. Pradalier,et al.  Sublingual‐swallow immunotherapy (SLIT) with a standardized five‐grass‐pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis , 1999, Allergy.

[15]  G. Canonica,et al.  Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. , 1999, The Journal of allergy and clinical immunology.

[16]  P. Papageorgiou,et al.  Double‐blind, placebo‐controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization , 1998, Allergy.

[17]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[18]  J. Bousquet,et al.  Clinical efficacy of sublingual‐swallow immunotherapy: a double‐blind, olacebo‐controlled trial of a standardized five‐grass‐pollen extract in rhinitis , 1998, Allergy.

[19]  A. Sabbah,et al.  A double‐blind, placebo‐controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract , 1994, Allergy.

[20]  C. André,et al.  A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. , 2003, International archives of allergy and immunology.

[21]  S. Voltolini,et al.  Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. , 1995, Journal of investigational allergology & clinical immunology.